Nightscout Dual View
CGM in the Cloud: A Community Unites to Tackle Diabetes
CGM in the Cloud is a concept first put forward by engineer (and father of a young son with type 1) John Costik early last year that, in a nutshell, entails taking a patient’s CGMs device real-time data, sending it to the cloud, and then allowing access to that data – again, in real-time – in remote locations, such as a webpage, a cell phone, or a wearable, like the popular Pebble smartwatch.
The Pump or Injections . . . or Both?
I’ve been on an insulin pump for about 13 years now, and I love the convenience of being able to dose insulin without additional injections,…
Novo Nordisk Logo
Novo Nordisk’s Type 2 Diabetes Drug Xultophy Approved in the EU
Novo Nordisk has been granted marketing authorization by the European Commission for a new injectable, Xultophy, for the treatment of Type 2 diabetes in adults. Xultophy is the brand name for IDegLira, the first once-daily single injection combination of insulin degludec (Tresiba) and liraglutide (Victoza).
Chocolate Peanut Butter Whoopie Pies 2
Chocolate Peanut Butter Whoopie Pies
Is there anything better than chocolate and peanut butter together? I think not. These whoopie pies are big on chocolate flavor with a delicious creamy peanut butter filling. The ultimate indulgence that is also sugar-free and gluten-free.
Novo Nordisk Logo
Novo Nordisk’s Ryzodeg Does The Job With Fewer Injections
Data presented today at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD) show that Ryzodeg (insulin degludec/insulin aspart) administered twice daily, provides successful glycaemic control with fewer injections than a basal-bolus regimen for type 2 diabetes patients. Ryzodeg is a combination of two distinct insulin analogues , insulin degludec (Tresiba) and insulin aspart (Novolog) in the ratio of 70% and 30%, making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.
JDRF New Logo
JDRF and Tidepool Partner to Bring Data to an Open Source Platform for People with Type 1 Diabetes
JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, and Tidepool, a Silicon Valley-based non-profit organization committed to reducing the burden of T1D, announced a partnership supported by JDRF funding for data access technology for people with T1D who use insulin pumps and continuous glucose monitors (CGMs) through a device agnostic cloud platform.
Let’s Stop Lying About Diabetes
You can’t “control” diabetes. The very nature of blood sugar — whether you have diabetes or not — is to go up and…
Novo Nordisk Logo
Novo Nordisk’s Tresiba Safe for Children with Type 1 Diabetes
Today, at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD), Novo Nordisk announced new data from the BEGIN® YOUNG 1 trial. The study investigates once-daily Tresiba (insulin degludec) versus basal insulin Levemir (detemir), both in combination with bolus insulin Novolog (aspart) in a 52-week trial in children and adolescents with type 1 diabetes. This trial is the first to look into the long-term safety of Tresiba in children and adolescents (from age 1 to less than 18 years) and the results show that Tresiba in combination with Novolog (Novorapid) effectively improved long-term glycemic control.